Skip to main content
MedVellum
MCQsExamsAtlas
DashboardPricing
MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳

MedVellum.

The folio

Exam-exhaustive medical education across every specialty — evidence-graded topics, engraved plates, and practice in every written and oral format. Educational content only — not medical advice.

llms.txt · psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship
  • Paediatrics Fellowship
  • Physician Medicine

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Folio edition · Set in Instrument Serif & Archivo

Paeds SAQsrespiratory-sleep-and-airway

Paeds SAQs · respiratory-sleep-and-airway

Bronchiectasis in children — short-answer question

Short-answer question on the definition and chronic suppurative lung disease continuum, the vicious cycle, the aetiological work-up, and the airway-clearance-and-antibiotic management of bronchiectasis in children.

20 marks30 min
On this page & tools

Target exams

RACP DWEMRCPCH TheoryABP General Pediatrics

Target exams

RACP DWEMRCPCH TheoryABP General Pediatrics
Prompt
A 6-year-old Aboriginal boy is referred with a daily wet cough that has persisted for three months and returns within days of each antibiotic course finishing. He has had several documented chest infections, is on the 10th centile for weight, and has early digital clubbing. A chest radiograph is reported as showing peribronchial changes only. Outline how you would define and explain his problem, how you would confirm the diagnosis and search for a cause, and your principles of management.

Part A — Definition, continuum and mechanism (10 marks)

a) Define bronchiectasis and explain the chronic suppurative lung disease continuum (4 marks)

Bronchiectasis is permanent, abnormal dilatation of the bronchi caused by chronic infection and inflammation, confirmed on chest high-resolution CT when a bronchus is wider than its adjacent artery. Its clinical hallmark, present long before any scan, is a chronic wet or productive cough lasting more than four weeks. Chronic suppurative lung disease describes the same child with the same wet cough and lower-airway neutrophilic infection whose HRCT does not yet meet radiological criteria for bronchiectasis. They are the same disease at different stages, so this boy's persistent wet cough should be treated as suppurative lung disease and the reversible front end of bronchiectasis. [1] [2]

b) Explain why his wet cough matters and outline the underlying mechanism (4 marks)

A wet cough that recurs the moment antibiotics stop signals an airway that cannot clear itself, not a run of viruses. The mechanism is a self-perpetuating vicious cycle: an initial insult impairs mucociliary clearance, secretions stagnate, bacteria colonise the pooled mucus, and chronic neutrophilic inflammation releases enzymes that destroy the airway wall, so the bronchus dilates and drains even worse. This locks in further infection and, if uninterrupted, ends in permanent dilatation. [1] [2]

c) State why early recognition is especially important in this child (2 marks)

In young children, early bronchiectasis on HRCT can regress with intensive treatment, so acting at the wet-cough stage can save the airway. This boy is also Aboriginal, and Aboriginal and Torres Strait Islander children carry among the highest rates of bronchiectasis in the world, much of it preventable, making early recognition both a clinical and an equity imperative. [2] [1]

Part B — Investigation and management (10 marks)

a) Outline how you would confirm the diagnosis and search for a cause (6 marks)

Because a plain film is insensitive and reports only peribronchial change, I would obtain a chest high-resolution CT to confirm bronchial dilatation and define its distribution. Bronchiectasis is a symptom, not a diagnosis, so I would work up the cause in every child: screen immune function with immunoglobulins and vaccine-response titres, exclude cystic fibrosis with a sweat test and genetics given the faltering growth, pursue primary ciliary dyskinesia with nasal nitric oxide and ciliary studies if the clinical cluster fits, and obtain a lower-airway culture from sputum or bronchoalveolar lavage to define the organisms and flag Pseudomonas aeruginosa. [1] [2]

b) Describe your principles of management (4 marks)

Management rests on daily airway clearance physiotherapy and prompt, prolonged, culture-guided antibiotics for exacerbations, treated for about two weeks rather than the short course used for a simple infection, with amoxicillin-clavulanate a common oral first-line agent and azithromycin a proven non-inferior alternative shown in the BEST-2 trial. I would optimise nutrition, ensure full immunisation, avoid tobacco smoke, treat the underlying cause, eradicate Pseudomonas if isolated, and place him in structured multidisciplinary respiratory follow-up delivered through culturally safe services. Long-term macrolide prophylaxis is reserved for a high exacerbation burden. [3] [2]

References

  1. [1]Chang AB, Bush A, Grimwood K Bronchiectasis in children: diagnosis and treatment. Lancet, 2018.PMID 30215382
  2. [2]Chang AB, Bell SC, Torzillo PJ, et al Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med J Aust, 2015.PMID 25588439
  3. [3]Goyal V, Grimwood K, Byrnes CA, et al Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet, 2018.PMID 30241722